Archives
-
COMET and Deep Learning for LNP Design
2026-10-08
Chan and colleagues introduce COMET, a transformer-based model designed to represent complete lipid nanoparticle formulations rather than isolated lipid molecules. Trained on the LANCE dataset, the model predicted formulation performance across several settings and identified candidates with strong protein expression, while the study also highlights important limits around dataset coverage, endpoint interpretation, and external validation.
-
Beyond GH Activity: Mapping the IGFBP2–THBS1 Axis
2026-10-07
Recent idiopathic short stature research reframes somatotropin biology around the IGFBP2–THBS1–IGF-1 network. This thought-leadership article examines how recombinant GH can support translational research, how to distinguish bioactivity from mechanism, and where the evidence remains insufficient for clinical extrapolation.
-
BAP1, Disulfidptosis, and Translational Strategy
2026-10-07
A source-grounded analysis of how BAP1, SLC7A11, cystine handling, and NADPH availability intersect in disulfidptosis research—and what this emerging biology means for translational strategy, biomarker development, and responsible compound positioning.
-
MERS-CoV RBD mRNA Vaccine: Evidence and Limits
2026-10-06
Tai et al. report that a nucleoside-modified mRNA encoding the MERS-CoV spike receptor-binding domain generated broad neutralizing antibodies, cellular responses, and protection in mice. The study links RNA stability, antigen-focused vaccine design, and administration route, while its preclinical scope limits direct translation to human mRNA vaccine development.
-
Mithramycin A Beyond c-Myc: A Translational Lens
2026-10-05
Mithramycin A offers a mechanistically informative way to interrogate G-C-rich transcription, c-myc regulation, and differentiation biology. This thought-leadership perspective connects that pharmacology with recent miR-24-3p/Sp1/PI3K findings in doxorubicin-associated cardiac injury while separating established evidence from translational hypotheses.
-
Sitagliptin Phosphate and Intestinal Stretch
2026-10-05
Sitagliptin phosphate monohydrate is a selective DPP-4 inhibitor used to investigate incretin biology and metabolic disease. This article examines how its GLP-1 and GIP mechanism should—and should not—be interpreted alongside new evidence that intestinal stretch can regulate feeding and glucose independently of classical GLP-1 signaling.
-
Mapping Pseudouridine in Cellular and Viral RNA
2026-10-04
Martinez Campos and colleagues introduced PA-Ψ-seq, an antibody-based method for mapping pseudouridine at transcript-level resolution. Their findings assigned several cellular mRNA sites to PUS1, PUS7, and TRUB1/PUS4, while HIV-1 RNA pseudouridine remained unchanged after loss of these enzymes, highlighting unresolved mechanisms in viral and cellular RNA modification.
-
Palonosetron: Selectivity, PK, and CINV Evidence
2026-10-03
The 2010 review of palonosetron hydrochloride integrates receptor pharmacology, animal antiemetic models, pharmacokinetics, and comparative clinical evidence. Its central contribution is the interpretation that highly selective 5-HT3 receptor antagonism combined with an approximately 40-hour half-life may extend protection into the delayed phase of chemotherapy-induced nausea and vomiting, although the review’s evidence is historical and not a systematic contemporary assessment.
-
U 46619: From TP Signaling to Translation
2026-10-02
U 46619 is a defined TP-receptor agonist for connecting platelet-proximal signaling with vascular phenotypes. This thought-leadership article explains how to use its response hierarchy, experimental controls, and translational framing to build more decision-ready cardiovascular studies.
-
Rosiglitazone and Adipose Thermogenesis
2026-10-01
Rosiglitazone, also known as Brl-49653, is a PPARγ agonist that can help separate adipocyte differentiation from thermogenic function in metabolic research. This article applies new SETD7–Adcy7–Sirt1–CREB1 findings to practical assay design and interpretation.
-
(+)-Bicuculline: Practical Workflow
2026-10-01
(+)-Bicuculline provides a controlled way to interrogate GABAA receptor-mediated inhibition and related neuronal signaling workflows when aqueous solubility limits preparation choices. This guide is for research use only and should not be used for diagnostic, therapeutic, or medical applications.
-
Panobinostat (LBH589) Cancer Assay Workflow
2026-09-30
Panobinostat (LBH589) supports epigenetic target engagement studies and cancer-response profiling across leukemia, multiple myeloma, and treatment-resistant breast cancer models. This workflow pairs histone-acetylation measurements with time-resolved viability and cell-death assays so growth arrest is not mistaken for apoptosis.
-
Pazopanib Hydrochloride: From Target to Translation
2026-09-30
Pazopanib Hydrochloride and GW786034 offer a useful framework for connecting multi-target kinase inhibition with more rigorous cancer drug-response analysis. This thought-leadership article explains how to distinguish proliferative arrest from cell death, design stronger translational assays, and interpret anti-angiogenic activity in renal cell carcinoma and soft tissue sarcoma research.
-
Chemoproteomic Mapping of CDK4–4E-BP1 Signaling
2026-09-29
Mitchell, Menon, and Garner developed PhAXA, a phosphosite-aware chemoproteomic strategy that identifies kinase–substrate relationships that are difficult to capture by conventional interaction assays. The study revealed that CDK4 phosphorylates the translational suppressor 4E-BP1, helping sustain cap-dependent translation and c-Myc production during mTORC1 inhibitor treatment in breast cancer models.
-
Dexamethasone (DHAP): Mechanism to Translation
2026-09-29
Dexamethasone (DHAP) is more than a broadly acting glucocorticoid anti-inflammatory: it is a controllable perturbation for studying NF-κB activity, dendritic-cell maturation, mesenchymal stem cell differentiation, autophagy, osteosarcoma biology, and neuroinflammation. This thought-leadership perspective connects mechanism, model selection, route of administration, temporal endpoints, and translational decision-making while defining where the evidence is mature and where researchers should remain cautious.